Table 2. Patient characteristics according to serum sPD-L1 levels pre- or post-chemoradiotherapy.
| Pre-CRT (N = 117) | Post CRT (N = 91) | |||||
|---|---|---|---|---|---|---|
| sPD-L1 low (N = 87) | sPD-L1 high (N = 30) | P | sPD-L1 low (N = 45) | sPD-L1 high (N = 46) | P | |
| Sex | 0.436 | 0.274 | ||||
| Male | 59 (67.8%) | 18 (60.0%) | 27 (60.0%) | 33 (71.7%) | ||
| Female | 28 (32.2%) | 12 (40.0%) | 18 (40.0%) | 13 (28.3%) | ||
| Age (years) (range) | 63 (27–79) | 57 (29–75) | 0.044 | 63 (34–77) | 61 (27–79) | 0.744 |
| Distance of tumor from AV (mm) (range) | 40 (0–80) | 35 (0–70) | 0.096 | 40 (0–70) | 40 (0–80) | 0.745 |
| Pretreatment CEA (ng/mL) (range) | 3.5 (0.5–104.1) | 3.4 (0.9–12.6) | 0.195 | 3.4 (1.2–58.5) | 3.4 (0.5–104.1) | 0.411 |
| Operative procedure | 0.591 | 0.207 | ||||
| Low anterior resection | 36 (41.4%) | 10 (33.3%) | 21 (46.7%) | 14 (30.4%) | ||
| Intersphincteric resection | 26 (29.9%) | 8 (26.7%) | 11 (24.4%) | 18 (39.1%) | ||
| Hartmann’s procedure | 1 (1.1%) | 0 (0%) | 1 (2.2%) | 0 (0%) | ||
| Abdominoperineal resection | 24 (27.6%) | 12 (40.0%) | 12 (26.7%) | 14 (30.4%) | ||
| Clinical T category | 0.247 | 0.573 | ||||
| T2 | 1 (1.1%) | 0 (%) | 1 (2.2%) | 0 (0%) | ||
| T3 | 80 (92.0%) | 25 (83.3%) | 40 (88.9%) | 41 (89.1%) | ||
| T4 | 6 (6.9%) | 5 (26.7%) | 4 (8.9%) | 5 (10.9%) | ||
| Clinical stage | 0.372 | 0.114 | ||||
| II | 43 (49.4%) | 12 (40.0%) | 27 (60.0%) | 20 (43.5%) | ||
| III | 44 (50.6%) | 18 (60.0%) | 18 (40.0%) | 26 (56.5%) | ||
| ypT category | 0.408 | 0.312 | ||||
| ypT0 | 10 (11.5% | 2 (6.7%) | 6 (13.3%) | 4 (8.7%) | ||
| ypTis | 2 (2.2%) | 0 (0%) | 2 (4.4%) | 0 (0%) | ||
| ypT1 | 9 (10.3%) | 1 (3.3%) | 2 (4.4%) | 3 (6.5%) | ||
| ypT2 | 26 (29.9%) | 14 (46.7%) | 19 (42.2%) | 14 (30.4%) | ||
| ypT3 | 39 (45.0%) | 12 (40.0%) | 16 (35.6%) | 23 (50.0%) | ||
| ypT4 | 1 (1.1%) | 1 (3.3%) | 0 (0%) | 2 (4.4%) | ||
| ypN category | 0.731 | 0.410 | ||||
| ypN0 | 69 (79.3%) | 23 (76.7%) | 38 (84.4%) | 36 (78.3%) | ||
| ypN1 | 13 (14.9%) | 6 (20.0%) | 6 (13.3%) | 10 (22.7%) | ||
| ypN2 | 5 (5.8%) | 1 (3.3%) | 1 (2.2%) | 0 (0%) | ||
| Tumor regression grade | 0.490 | 0.299 | ||||
| TRG1 | 27 (31.0%) | 10 (33.3%) | 11 (24.4%) | 18 (39.1%) | ||
| TRG2 | 45 (51.7%) | 18 (60.0%) | 27 (60.0%) | 20 (43.5%) | ||
| TRG3 | 4 (4.6%) | 0 (0%) | 1 (2.2%) | 3 (6.5%) | ||
| TRG4 | 11 (12.7%) | 2 (6.7%) | 6 (13.3%) | 5 (10.9%) | ||
| Histological type | 1.000 | 1.000 | ||||
| Well/moderate | 84 (96.5%) | 29 (96.7%) | 44 (97.8%) | 45 (97.8%) | ||
| Poor | 3 (3.5%) | 1 (3.3%) | 1 (2.2%) | 1 (2.2%) | ||
| Lymphovascular invasion | 0.077 | 0.021 | ||||
| Negative | 51 (58.6%) | 12 (40.0%) | 30 (66.7%) | 19 (41.3%) | ||
| Positive | 36 (41.4%) | 18 (60.0%) | 15 (33.3%) | 27 (58.7%) | ||
| Adjuvant chemotherapy | 0.434 | 0.824 | ||||
| No | 54 (62.1%) | 21 (70.0%) | 31 (68.9%) | 30 (65.2%) | ||
| Yes | 33 (37.9%) | 9 (30.0%) | 14 (31.1%) | 16 (44.8%) | ||
Data are n (%) or median (range). AV, anal verge. CEA, carcinoembryonic antigen. CRT, chemoradiotherapy. TRG, tumor regression grade.